{"schema_version":"1","generated_at":"2026-11-04T17:18:40.748Z","data_as_of":null,"url":"https://www.findmykol.com/kol/kamaneh-montazeri","json_url":"https://www.findmykol.com/kol/kamaneh-montazeri/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"kamaneh-montazeri","name":"Kamaneh Montazeri","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Massachusetts General Hospital","institution_url":"https://www.findmykol.com/institution/massachusetts-general-hospital","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1457766149","orcid":"0000-0003-3693-5994","openalex":"A5016868130"},"summary":"Kamaneh Montazeri is an Oncology physician affiliated with Massachusetts General Hospital. OpenAlex indexes 36 publications with 328 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":36,"cited_by_count":328,"h_index":9,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"TriSalus Life Sciences","program_year":2025,"amount_usd":12084.86,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1457766149"},{"payer":"TriSalus Life Sciences","program_year":2024,"amount_usd":178745.92,"payment_count":23,"source_url":"https://openpaymentsdata.cms.gov/search?query=1457766149"},{"payer":"Merck & Co.","program_year":2024,"amount_usd":78800,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1457766149"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1457766149","source":"payments"},"prescribing":{"data_year":2020,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":79.1,"classes_total":3,"classes":[{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":43.3,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":null},{"class":"Androgen Receptor Inhibitor","setting":"prescribed","share_pct":19.4,"drugs":[{"name":"Xtandi","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":20.9,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":20.9,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2020,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":36,"shown":5,"withheld":31,"matched_by":"OpenAlex author record","recent":[{"title":"Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.17_suppl.lba9503","status":"verified"},{"title":"An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","year":2026,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-026-04518-z","status":"verified"},{"title":"Abstract 3929: Prognostic significance of ctDNA in patients with metastatic uveal melanoma.","year":2026,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2026-3929","status":"verified"},{"title":"Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyaf323","status":"verified"},{"title":"Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-25-2274","status":"verified"}],"source":"works"},"similar":[{"name":"Keith Flaherty","slug":"keith-flaherty","institution":"Massachusetts General Hospital","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/keith-flaherty","json_url":"https://www.findmykol.com/kol/keith-flaherty/profile.json"},{"name":"Maurizio Fava","slug":"maurizio-fava","institution":"Massachusetts General Hospital","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/maurizio-fava","json_url":"https://www.findmykol.com/kol/maurizio-fava/profile.json"},{"name":"Andrew Zhu","slug":"andrew-zhu","institution":"Massachusetts General Hospital","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/andrew-zhu","json_url":"https://www.findmykol.com/kol/andrew-zhu/profile.json"},{"name":"Steven Greenberg","slug":"steven-greenberg","institution":"Massachusetts General Hospital","specialty":"Neurology","url":"https://www.findmykol.com/kol/steven-greenberg","json_url":"https://www.findmykol.com/kol/steven-greenberg/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":31}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}